Mendeley  

Zotero  

Tari K, Valizadeh Ardalan P, Abroun S. Venetoclax in T-cell Acute Lymphoblastic Leukemia: The Impact of BCL-2 Inhibition on Treatment Efficacy. Res Mol Med (RMM) 2023; 11 (4) :213-226
URL: http://rmm.mazums.ac.ir/article-1-550-en.html

T-cell acute lymphoblastic leukemia (T-ALL) is a rare and aggressive leukemia that targets T-cells, a subtype of white blood cells. Despite advancements in treatment, T-ALL continues to be a formidable disease to manage, characterized by high relapse rates and a dismal prognosis. Recent studies have underscored the promise of B-cell lymphoma 2 (BCL-2) inhibition as a treatment approach for T-ALL. Venetoclax, an innovative BCL-2 inhibitor, has demonstrated encouraging outcomes in preclinical investigations. Inhibition of BCL-2 with venetoclax constitutes a unique and promising therapeutic strategy for T-ALL, with improved treatment results and fewer adverse effects. As researchers persist in investigating the efficacy of venetoclax and other BCL-2 inhibitors, patients with T-ALL may soon access more effective and focused treatments. Recent advancements in the research and development of combination medicines and the discovery of novel biomarkers offer the potential for enhanced treatment outcomes with venetoclax. This paper thoroughly examines the present state of BCL-2 inhibition in T-ALL and underscores the promise of venetoclax as an innovative therapeutic approach, stressing the necessity for additional research to harness its potential fully.